Sökning: WFRF:(Mikelarena BA) >
Targeted Therapy of...
Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors
-
- Kostopoulou, ON (författare)
- Karolinska Institutet
-
- Zupancic, M (författare)
- Karolinska Institutet
-
Pont, M (författare)
-
visa fler...
-
Papin, E (författare)
-
- Lukoseviciute, M (författare)
- Karolinska Institutet
-
Mikelarena, BA (författare)
-
- Holzhauser, S (författare)
- Karolinska Institutet
-
- Dalianis, T (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2022-06-23
- 2022
- Engelska.
-
Ingår i: Viruses. - : MDPI AG. - 1999-4915. ; 14:7
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- Human papillomavirus positive (HPV+) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) have a favorable outcome, but upon relapse, survival is poor and new therapeutical options are needed. Recently, we found synergistic effects by combining the food and drug administration approved (FDA) phosphoinositide 3-kinase (PI3K) and fibroblast-growth-factor-receptor (FGFR) inhibitors BYL719 and JNJ-42756493 on TSCC cell lines. Here this approach was extended and Cyclin-Dependent-Kinase-4/6 (CDK4/6) and Poly-ADP-ribose-polymerase (PARP) and WEE1 inhibitors PD-0332991, and MK-1775 respectively were also examined. HPV+ CU-OP-2, -3, -20, and HPV− CU-OP-17 TSCC cell lines were treated with either BYL719 and JNJ-42756493, PD-0332991 BMN-673 and MK-1775 alone or in different combinations. Viability, proliferation, and cytotoxicity were followed by WST-1 assays and the IncuCyte S3 Live® Cell Analysis System. All inhibitors presented dose-dependent inhibitory effects on tested TSCC lines. Synergy was frequently obtained when combining CDK4/6 with PI3K inhibitors, but only sometimes or rarely when combining CDK4/6 with FGFR inhibitors or PARP with WEE1 inhibitors. To conclude, using CDK4/6 with PI3K or FGFR inhibitors, especially PD-0332991 with BYL719 presented synergy and enhanced the decrease of viability considerably, while although dose dependent responses were obtained with PARP and WEE1 inhibitors (BMN-673 and MK-1775 resp.), synergy was rarely disclosed.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Viruses
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas